{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:36:29Z","timestamp":1769121389625,"version":"3.49.0"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":2106,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:p><jats:bold>Study Objective<\/jats:bold>. To determine the proportion of patients in a large metropolitan population who developed ischemic stroke despite having received antiplatelet drug therapy, and their associated characteristics and in\u2010hospital outcomes.<\/jats:p><jats:p><jats:bold>Design<\/jats:bold>. Retrospective, cross\u2010sectional study.<\/jats:p><jats:p><jats:bold>Setting<\/jats:bold>. Eleven hospitals in western New York State.<\/jats:p><jats:p><jats:bold>Patients<\/jats:bold>. One thousand five hundred eighty\u2010two patients with new or recurrent ischemic stroke who were admitted to one of the 11 study hospitals between January 1 and December 31, 2000, and for whom data were available regarding previous drug therapy.<\/jats:p><jats:p><jats:bold>Measurements and Main Results<\/jats:bold>. The proportion of patients taking antiplatelet drugs before the onset of stroke was determined. Demographic and clinical characteristics, stroke subtypes, in\u2010hospital bleeding complications, mortality, and discharge drugs were compared between patients with and those without previous antiplatelet drug use. Previous use of antiplatelet drugs was observed in 642 (41%) of the 1582 patients admitted with ischemic stroke. The antiplatelet drugs were aspirin alone (494 patients), clopidogrel alone (70), aspirin and clopidogrel (36), aspirin in combination with other antiplatelet drugs (20), and others (22). Patients with previous use of antiplatelet drugs were older and more likely to have hypertension, diabetes mellitus, hyperlipidemia, and a history of cardiovascular disease. The proportion of patients with large\u2010vessel disease was greater among patients with previous use of antiplatelet drugs. Patients with previous use of antiplatelet drugs were more likely to be discharged with aspirin, clopidogrel, and an aspirin\u2010dipyridamole combination.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold>. The relatively high proportion of patients who developed ischemic stroke despite taking antiplatelet drugs observed in this regional hospital\u2010based study mandates clinical trials specifically addressing therapeutic intervention for this group of patients.<\/jats:p>","DOI":"10.1592\/phco.26.4.493","type":"journal-article","created":{"date-parts":[[2006,3,22]],"date-time":"2006-03-22T08:13:12Z","timestamp":1143015192000},"page":"493-498","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["High Prevalence of Previous Antiplatelet Drug Use in Patients with New or Recurrent Ischemic Stroke: Buffalo Metropolitan Area and Erie County Stroke Study"],"prefix":"10.1002","volume":"26","author":[{"given":"Adnan I.","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawad F.","family":"Kirmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Safdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafiuddin","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad A.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi U.","family":"Pande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda A.","family":"Hershey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid J.","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000075298"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000075299"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.30.11.2502"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000064841.47697.22"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011258"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043033"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000080095"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.21.4.637"},{"key":"e_1_2_1_10_2","first-page":"373","article-title":"Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989","volume":"27","author":"Brown RD","year":"1996","journal-title":"Stroke"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.10.1236"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.23.9.1250"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.19.5.604"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.37991.635266.44"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1179\/016164101101198668"},{"key":"e_1_2_1_16_2","first-page":"569","article-title":"Factors associated to aspirin failure for secondary stroke prevention [in Spanish]","volume":"109","author":"Chamorro A","year":"1997","journal-title":"Med Clin (Barc)"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.1.111"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.4.490"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.29.2.415"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwf152"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.26.4.493","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.26.4.493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:50:34Z","timestamp":1761054634000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.26.4.493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1592\/phco.26.4.493"],"URL":"https:\/\/doi.org\/10.1592\/phco.26.4.493","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}